Literature DB >> 23002015

Animal models of Alzheimer disease.

Frank M LaFerla1, Kim N Green.   

Abstract

Significant insights into the function of genes associated with Alzheimer disease and related dementias have occurred through studying genetically modified animals. Although none of the existing models fully reproduces the complete spectrum of this insidious human disease, critical aspects of Alzheimer pathology and disease processes can be experimentally recapitulated. Genetically modified animal models have helped advance our understanding of the underlying mechanisms of disease and have proven to be invaluable in the preclinical evaluation of potential therapeutic interventions. Continuing refinement and evolution to yield the next generation of animal models will facilitate successes in producing greater translational concordance between preclinical studies and human clinical trials and eventually lead to the introduction of novel therapies into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23002015      PMCID: PMC3543097          DOI: 10.1101/cshperspect.a006320

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  87 in total

1.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

2.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

3.  Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

Authors:  Patrick R Verhoest; Caroline Proulx-Lafrance; Michael Corman; Lois Chenard; Christopher J Helal; Xinjun Hou; Robin Kleiman; Shenping Liu; Eric Marr; Frank S Menniti; Christopher J Schmidt; Michelle Vanase-Frawley; Anne W Schmidt; Robert D Williams; Frederick R Nelson; Kari R Fonseca; Spiros Liras
Journal:  J Med Chem       Date:  2009-12-24       Impact factor: 7.446

4.  Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application.

Authors:  Andreas Lerchner; Rainer Machauer; Claudia Betschart; Siem Veenstra; Heinrich Rueeger; Clive McCarthy; Marina Tintelnot-Blomley; Anne-Lise Jaton; Sabine Rabe; Sandrine Desrayaud; Albert Enz; Matthias Staufenbiel; Paolo Paganetti; Jean-Michel Rondeau; Ulf Neumann
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

5.  Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations.

Authors:  Ju-Hyun Lee; W Haung Yu; Asok Kumar; Sooyeon Lee; Panaiyur S Mohan; Corrinne M Peterhoff; Devin M Wolfe; Marta Martinez-Vicente; Ashish C Massey; Guy Sovak; Yasuo Uchiyama; David Westaway; Ana Maria Cuervo; Ralph A Nixon
Journal:  Cell       Date:  2010-06-10       Impact factor: 41.582

6.  Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

Authors:  Lars M Ittner; Yazi D Ke; Fabien Delerue; Mian Bi; Amadeus Gladbach; Janet van Eersel; Heidrun Wölfing; Billy C Chieng; MacDonald J Christie; Ian A Napier; Anne Eckert; Matthias Staufenbiel; Edna Hardeman; Jürgen Götz
Journal:  Cell       Date:  2010-07-22       Impact factor: 41.582

7.  PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.

Authors:  Noel G Faux; Craig W Ritchie; Adam Gunn; Alan Rembach; Andrew Tsatsanis; Justin Bedo; John Harrison; Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Martin Ingelsson; Colin L Masters; Rudolph E Tanzi; Jeffrey L Cummings; Caroline M Herd; Ashley I Bush
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 8.  Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Authors:  Delphine Boche; Nathan Denham; Clive Holmes; James A R Nicoll
Journal:  Acta Neuropathol       Date:  2010-07-15       Impact factor: 17.088

9.  Klotho is a substrate for alpha-, beta- and gamma-secretase.

Authors:  Laura Bloch; Olga Sineshchekova; Daniela Reichenbach; Karina Reiss; Paul Saftig; Makoto Kuro-o; Christoph Kaether
Journal:  FEBS Lett       Date:  2009-09-06       Impact factor: 4.124

10.  Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation.

Authors:  Olivia A Shipton; Julie R Leitz; Jenny Dworzak; Christine E J Acton; Elizabeth M Tunbridge; Franziska Denk; Hana N Dawson; Michael P Vitek; Richard Wade-Martins; Ole Paulsen; Mariana Vargas-Caballero
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

View more
  136 in total

Review 1.  Deciphering Alzheimer disease.

Authors:  Dennis Selkoe; Eckhard Mandelkow; David Holtzman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model.

Authors:  Ning Cheng; Li Bai; Elizabeth Steuer; Leonardo Belluscio
Journal:  J Neurosci       Date:  2013-07-24       Impact factor: 6.167

Review 4.  Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse".

Authors:  Madhav Thambisetty
Journal:  Am J Physiol Cell Physiol       Date:  2017-06-14       Impact factor: 4.249

5.  Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques.

Authors:  Swetha Gowrishankar; Peng Yuan; Yumei Wu; Matthew Schrag; Summer Paradise; Jaime Grutzendler; Pietro De Camilli; Shawn M Ferguson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

Review 6.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 7.  Large Animal Models of Huntington's Disease.

Authors:  Xiao-Jiang Li; Shihua Li
Journal:  Curr Top Behav Neurosci       Date:  2015

Review 8.  Neural functions of bisecting GlcNAc.

Authors:  Yasuhiko Kizuka; Naoyuki Taniguchi
Journal:  Glycoconj J       Date:  2018-06-16       Impact factor: 2.916

Review 9.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

10.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.